Henry Schein has lined up a number of significant events recently, starting with the appointment of a new CEO,
Frederick M. Lowery, who brings a wealth of industry experience. The firm's rotational strategy timing, margin improvement potential, and its impact on shareholder value are topics of interest, particularly given stalled returns on capital. A new agreement with
CitoCBC has launched exclusive distribution of its products. Investors are keenly observing the company's quarterly earnings, witnessing a beat in Q3 estimates as well as a surge in earnings by 24%. Nonetheless, shares fluctuated with some declines amid the news. The
Curodont deal expansion might reshape HSIC's margin story, an aspect on which the 2025 outlook hinges. The company faces challenges in valuation, despite recent share price momentum. It has been compared with other dental equipment and technology stocks and has lifted its 2025 guidance, making HSIC a potential value buy for the long-term.
Henry Schein HSIC News Analytics from Mon, 05 May 2025 07:00:00 GMT to Sat, 31 Jan 2026 16:23:48 GMT -
Rating 5
- Innovation 6
- Information 7
- Rumor -3
